Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 89
- 试验地点
- 2
- 主要终点
- Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass
研究概览
简要总结
HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and sphingolipids in the HDL. These molecules play a major role in HDL function and probably present early modifications in obesity, even before the onset of glycaemia deregulation.
The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •aged > 18 years
- •fasting glycaemia < 1.10 g/l
- •waist circumference > 102 cm for men and 88 cm for women (criteria NCEP/ATP III)
- •2 criteria among the following 3 (NCEP/ATP III criteria for metabolic syndrome):
- •triglyceridaemia ≥ 1.50 g/l
- •HDL cholesterol < 0.40 g/l for men and 0.50 g/l for women
- •arterial blood pressure ≥ 130/85 mmHg or treatment for arterial hypertension
- •patients who have provided written consent INCLUSION CRITERIA FOR HEALTHY SUBJECTS
- •age > 18 years
- •fasting glycaemia < 1.10 g/l
- •waist circumference < 102 cm for men and 88 cm for women
- •triglyceridaemia < 1.50 g/l
- •HDL cholesterol ≥ 0.40 g/l for men and 0.50 g/l for women
- •Healthy subjects who have provided written consent
排除标准
- •Persons without national health insurance cover
- •Diseases that interfere with lipoprotein metabolism (dysthyroidism not controlled with the treatment, kidney or liver disease)
- •Treatments that interfere with lipoprotein metabolism (lipid-lowering agents, oestrogens, corticoids, retinoids, antiretroviral agents)
- •Pregnancy/breast feeding
研究组 & 干预措施
Obese
干预措施: Blood sample (Biological)
control
干预措施: Blood sample (Biological)
结局指标
主要结局
Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass
时间窗: At inclusion
in patients with abdominal obesity without hyperglycaemia compared with healthy controls
次要结局
- Difference in the percentage of each sub-family according to the nature of the fatty acids for phosphatidylcholines on the one hand and sphingomyelins on the other in patients(At inclusion)
- Difference in the percentage of each family of phospholipids or sphingolipids compared with total phospholipids + sphingolipids(At inclusion)